Medline Inc. Class A Common Stock annual ebitda for fiscal TTM was $2.7 billion, an increase of 39.9% from $2.0 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| EBITDA | $2.7B | $2.0B | $3.5B | $2.6B | $1.9B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|
| EBITDA | $681M | $382M | $826M | $842M | $799M | $760M | $806M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More MDLN metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All MDLN financial statements → Interactive MDLN charts →
About TickerBase · Data methodology & sources